A director at Bumrungrad Hospital Public Company Limited bought 100,000 shares at 176.000THB and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
The tone at BH’s 2Q25 analyst meeting was positive. Management provided a positive development update on the Kuwaiti patient issue, indicating that it should be resolved soon. The 3Q25 guidance is also promising as last year’s base will no longer include the Kuwait patient portion and revenue intensity is expected to improve. We are more positive on BH, but the timeline and the magnitude of Kuwaiti patients’ return is still uncertain, and the market has already priced this in. Maintain HOLD...
KEY HIGHLIGHTS Sector Property Expect earnings to recover in 2Q25, but 2H25 outlook remains uncertain. Update Bumrungrad Hospital (BH TB/HOLD/Bt176.50/Target: Bt185.00) Cautiously optimistic in 2H25. Kasikorn Bank (KBANK TB/BUY/Bt160.50/Target: Bt192.00 To increase dividend policy from 25% to 50% and guide for potential capital management.
GREATER CHINA Strategy Alpha Picks: August Conviction Calls: Add JBM Healthcare and Lenovo to our BUY list. Take profit on CATL, Han’s Laser, KE Holdings and Longfor. INDONESIA Strategy 1H25 Results Recap: Among the 40 stocks under our coverage that have announced their results, 25% beat forecasts, 39% were in line and 35% were below expectations. Results Indofood CBP (ICBP IJ/BUY/Rp9,550/Target: Rp13,800): 1H25: Core profit in line with our expectation. MALAYSIA Update Alpha IVF (ALPHA MK/BUY...
BH is expected to report a net profit of Bt1.7b (-11.4% yoy, -1.3% qoq) in 2Q25. Top-line should be weak at Bt6.0b (-5.0% yoy, -2.5% qoq), as it continues to be pressured by the slower return of Middle Eastern patients and the Thai-Cambodia conflict which will likely lead to a slowdown in Cambodian patient arrivals. We remain cautious on BH as there are still several overhangs related to foreign patient markets that could cause a further decline in revenue intensity just like in 1Q25. Maint...
GREATER CHINA Update Xtep International Holdings (1368 HK/BUY/HK$5.34/Target: HK$8.00) Confident in achieving full-year targets; Saucony on track to reach mid-term goal. INDONESIA Small/Mid Cap Highlights Bank KB Bukopin (BBKP IJ/NOT RATED/Rp60) Turnaround hinges on CoF reduction. MALAYSIA Update Kuala Lumpur Kepong (KLK MK/HOLD/RM20.46/Target: RM20.50) We expect 3QFY25 results to come in flat qoq, supported by firmer plantation output and lower forex ...
GREATER CHINA Economics Economic Activity Mixed bag for May. Sector Property Property market weakens further in May 25, with diverging city-tier performance. INDONESIA Initiate Coverage Bumi Resources Minerals (BRMS IJ/BUY/Rp454/Target: Rp610) Soaring to new heights; initiate coverage with BUY. MALAYSIA Update Press Metal ...
GREATER CHINA Sector Macau Gaming: Apr 25 GGR beat expectations; May Day Golden Week visitor arrivals expected to grow 4% yoy. Results ASMPT (522 HK/BUY/HK$52.20/Target: HK$68.00): 1Q25: Earnings disappoint; mainstream tools recovering in 2025 but visibility remains low. Maintain BUY. China Tourism Group Duty Free (601888 CH/BUY/Rmb63.40/Target: Rmb70.80): 1Q25: Core net profit down 16% yoy; sequential improvement in Hainan duty-free sales. Ganfeng Lithium (1772 HK/BUY/HK$18.94/Target: HK$30.00)...
The tone at BH’s 1Q25 analyst meeting was negative. Management still does not expect a rebound in hospital revenue as a result of the earthquake in Mar 25. The drop in revenue intensity in 1Q25 could become a concern if it becomes a recurring trend. Despite the positive development in Saudi Arabia and Bangladesh, we are less optimistic on BH as it lacks a substantial catalyst to improve its earnings. Downgrade to HOLD. Target price: Bt178.00.
KEY HIGHLIGHTS Sector Property 1Q25 earnings under pressure; recovery outlook remains uncertain. Update Asset World Corporation (AWC TB/BUY/Bt2.20/Target: Bt3.30) Expect strong earnings growth in 1Q25. Bumrungrad Hospital (BH TB/HOLD/Bt168.50/Target: Bt178.00) Less optimistic on foreign patient numbers. Downgrade to HOLD. Siam Cement (SCC TB/HOLD/Bt160.00/Target: Bt160.00) Timeline for the LSP project to resume operations remains uncertain.
BH reported a net profit of Bt1.73b (-12.6% yoy, -8.9% qoq) in 1Q25, which is in line with our and consensus estimates. The high base last year and the earlier timing of Ramadan this year caused top-line to drop by 6.1% yoy. Growth in revenue from Thai patients was weak at 1.3% yoy and was not sufficient to compensate for the shortfall in foreign patient revenue. We are more optimistic about BH’s 2Q25 outlook as the impact from Ramadan was already realised in 1Q25. Maintain BUY. Target pric...
KEY HIGHLIGHTS Sector Banking 1Q25: Results beat; banks prioritise less on loan growth. Downgrade to MARKET WEIGHT. Results Bumrungrad Hospital (BH TB/BUY/Bt169.00/Target: Bt232.00) 1Q25: Weak results in line with expectations. Update Thai Foods Group (TFG TB/BUY/Bt5.05/Target: Bt6.70) Expect record-high earnings in 1Q25 and 2Q25. Thanachart Capital (TCAP TB/HOLD/Bt47.00/Target: Bt48....
GREATER CHINA Results Aier Eye Hospital Group (300015 CH/BUY/Rmb12.72/Target: Rmb17.80) 2024: Satisfactory results; expects strong recovery in 2025. Upgrade to BUY. Ningbo Tuopu Group Co (601689 CH/BUY/Rmb50.96/Target: Rmb83.00) 4Q24: Earnings up 38.5% yoy, in line. Maintain BUY with target price unchanged at Rmb83.00. TAL Educational Group (TAL US/BUY/US$9.36/Target: US$14.00) 4QFY25: Earnings miss amid ramped-up investments in AI-powered learning. INDONESIA Sector Telecommun...
We expect BH to report a net profit of Bt1.7b in 1Q25 (-13.2% yoy, -9.4% qoq). Top-line should be weak at Bt6.1b (-6.5% yoy, -5.6% qoq) due to the high base last year and the earlier timing of Ramadan this year. As a result, the expected decrease in Middle Eastern patient volume should also lead to a yoy margin contraction. We expect the 2Q25 outlook to improve, as a yoy growth will come off a more normalised base in 2Q24. Maintain BUY. Target price: Bt232.00.
KEY HIGHLIGHTS Results Bangkok Bank (BBL TB/HOLD/Bt146.50/Target: Bt154.00) 1Q25: Results beat expectations; investment gain boosted the bottom line. TISCO Financial Group (TISCO TB/HOLD/Bt100.00/Target: Bt94.00) 1Q25: Results in line; revises down 2025 credit cost target to 100bp. Update Bumrungrad Hospital (BH TB/BUY/Bt168.00/Target: Bt232.00) Expect weak 1Q25 earnings due to margin pressure.
We attended BH’s 4Q24 analyst meeting and the tone was neutral. The strong growth of Thai patients in 4Q24 was attributable to the health checkup season. There have been favourable developments in Middle Eastern countries like Kuwait and Saudi Arabia but a definite timeline is still lacking. We believe that earnings growth in 1Q25 will be challenging due to the shortfall in Kuwait. However, we expect to see a gradual improvement from 2Q25 onwards. Maintain BUY. Target price: Bt232.00.
Update Bumrungrad Hospital (BH TB/BUY/Bt195.50/Target: Bt232.00) Outlook for foreign patients remains under observation. Origin Property (ORI TB/HOLD/Bt2.68/Target: Bt2.90) Conservative 2025 business plan focusing on financial stability. Stecon Group (STECON TB/BUY/Bt5.40/Target: Bt6.50) Overhang clears; earnings recovery in sight
GREATER CHINA Economics Highlights From The NPC: A comprehensive response to economic challenges. Update Cathay Pacific Airways (293 HK/HOLD/HK$10.76/Target: HK$11.30): Cathay’s stellar 2024 earnings performance is unlikely to be sustainable in the long run, but a potential beat of street estimates may still provide a near-term trading opportunity. INDONESIA Update Bank Rakyat Indonesia (BBRI IJ/BUY/Rp3,840/Target: Rp4,500): Spike in CoC in 1Q25; focus on cleaning up loans. MALAYSIA Sector Tec...
BH reported a net profit of Bt1.9b in 4Q24 (+10.6% yoy, -2.7% qoq), above our expectations but in line with consensus’. The strong earnings were mainly contributed by the utilisation of tax benefit in the quarter. Top-line came in at Bt6.5b, down slightly yoy due to the continuous drop in foreign patient revenue, partly offset by the strong growth of Thai patients. We expect to see slight growth in 1Q25 with a mixed outlook. Maintain BUY. Target price: Bt232.00.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.